ISSN:
1573-0646
Keywords:
piroxantrone
;
adenocarcinoma of the pancreas
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0% –10%). Toxicities of grade ≥ 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00874432